{'fraction_non_alphanumeric': 0.016701461377870562, 'fraction_numerical': 0.009046624913013222, 'mean_word_length': 5.688372093023256, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hematopoietic transplantation: State of the art

Bone marrow transplantation has developed from an experimental therapy for a small group of patients to a well‐established form of treatment with well‐defined indications for a large group of patients with hematological and non‐hematological neoplasia. The availability of suitable donors has more than doubled due to large registries of persons volunteering for marrow donation. With improved techniques for histocompatibility typing, it has become possible to study the role of specific histoincompatibilities for graft‐versus‐host disease and graft‐versus‐leukemia reactions. The source of hematopoietic stem cells now comprises not only bone marrow, but also stem cells mobilized into the peripheral blood and stem cells from cord blood. Hematopoietic growth factors have found a large distribution in the mobilization of stem cells and support for hematological reconstitution. They are studied for the expansion of pools of stem cells. Reconstitution of antileukemia and antiviral activity has been achieved by adoptive immunotherapy using lymphocytes and dendritic cells cultured in vitro. The way from transplantation of bone marrow to cellular and genetic engineering leads to new indications such as treatment of severe autimmune disease. Hematopoietic transplantation has come a long way and it still has possible new areas of application. Stem Cells 1997; 15(suppl 1): 151‐158